Noradrenalina Tartrato Galenica Senese (Noradrenaline Tartrate)

Noradrenaline tartrate acts as a direct agonist at α1‑adrenergic receptors on vascular smooth muscle, causing strong vasoconstriction and an increase in systemic vascular resistance. The resulting rise in mean arterial pressure improves perfusion of vital organs. It also provides modest β1‑adrenergic stimulation, which can increase heart rate and contractility, further supporting circulatory function.

The dose of noradrenaline tartrate is individualized by the prescribing clinician. It is usually started at a low infusion rate and titrated based on continuous blood pressure monitoring to achieve a target mean arterial pressure. The exact amount, concentration and duration depend on the patient’s clinical status, response, and institutional protocols.

Safety data for noradrenaline tartrate in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling where required—and the necessary import documentation.

Compared with agents such as dopamine or phenylephrine, noradrenaline tartrate provides a more potent α1‑mediated vasoconstrictive effect with relatively less tachycardia. Dopamine has dose‑dependent β‑ and α‑effects, while phenylephrine is a pure α‑agonist. Clinicians often prefer noradrenaline for septic shock because it reliably raises blood pressure while preserving cardiac output.

Noradrenalina Tartrato Galenica Senese must be stored at 2‑8 °C in a refrigerator. The vial should be kept in its original packaging, protected from light, and must not be frozen or shaken. Maintaining the cold chain is essential to preserve drug stability and efficacy.

The medication is supplied as an injectable solution for intravenous use. It is typically diluted in a compatible carrier fluid and delivered via a controlled infusion pump. Administration should be performed by trained healthcare personnel, with continuous monitoring of arterial pressure and heart rate to allow rapid dose adjustments.

The most critical adverse events include cardiac arrhythmias, myocardial ischemia, and tissue necrosis due to extreme peripheral vasoconstriction. These complications can be life‑threatening and require immediate recognition, cessation of the infusion, and appropriate medical intervention. Regular ECG monitoring and assessment of peripheral perfusion are recommended.

Noradrenaline tartrate is contraindicated in patients with known severe peripheral vascular disease, uncontrolled hypertension, or those who have experienced hypersensitivity to noradrenaline or any formulation component. Caution is also advised in individuals with existing cardiac arrhythmias or acute myocardial infarction, where alternative therapies may be preferred.